Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose ...

As part of Livewire’s annual Outlook Series, we recently asked 10 of Australia’s top fund managers to answer which industries ...